Published in J Am Acad Child Adolesc Psychiatry on April 01, 2006
Treatment of Autism in Children and Adolescents | NCT00005014
The role of adaptive behavior in autism spectrum disorders: implications for functional outcome. J Autism Dev Disord (2011) 1.60
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2009) 1.55
Developmental trajectories in adolescents and adults with autism: the case of daily living skills. J Am Acad Child Adolesc Psychiatry (2012) 1.24
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol (2009) 1.06
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. J Am Acad Child Adolesc Psychiatry (2011) 1.05
Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology (2009) 1.00
Educational placements and service use patterns of individuals with autism spectrum disorders. J Autism Dev Disord (2006) 0.96
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord (2008) 0.96
Brief report: The assessment of anxiety in high-functioning adolescents with autism spectrum disorder. J Autism Dev Disord (2012) 0.95
Measuring change in social interaction skills of young children with autism. J Autism Dev Disord (2012) 0.95
Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J (2011) 0.89
Developmental disabilities modification of the Children's Global Assessment Scale. Biol Psychiatry (2007) 0.86
Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study. J Child Adolesc Psychopharmacol (2014) 0.84
A pilot study of parent training in young children with autism spectrum disorders and disruptive behavior. J Autism Dev Disord (2013) 0.80
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol (2013) 0.79
Early-emerging social adaptive skills in toddlers with autism spectrum disorders: an item analysis. J Autism Dev Disord (2014) 0.77
Treatment of Autism Spectrum Disorder in Children and Adolescents. Psychopharmacol Bull (2016) 0.75
Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study. Indian J Psychol Med (2014) 0.75
Beyond irritability and aggressive behavior: does risperidone improve adaptive behavior in autistic spectrum disorders? Curr Psychiatry Rep (2007) 0.75
A Systematic Review and Meta-analysis of Parent Training for Disruptive Behavior in Children with Autism Spectrum Disorder. Clin Child Fam Psychol Rev (2017) 0.75
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 11.25
Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 10.19
Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry (2006) 10.00
Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry (2006) 9.98
Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 9.85
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature (2009) 9.47
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry (2009) 6.71
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 4.58
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry (2007) 3.78
Geographic variation in the prevalence of attention-deficit/hyperactivity disorder: the sunny perspective. Biol Psychiatry (2013) 3.47
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev (2009) 3.39
3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry (2007) 3.33
Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry (2009) 3.32
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA (2010) 3.28
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry (2009) 3.17
The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord (2007) 3.03
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 2.95
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. Am J Psychiatry (2007) 2.84
A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2009) 2.80
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry (2009) 2.69
Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry (2009) 2.65
Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry (2004) 2.63
Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med (2006) 2.62
Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A (2004) 2.58
Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry (2011) 2.55
Recent trends in stimulant medication use among U.S. children. Am J Psychiatry (2006) 2.52
The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry (2013) 2.48
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Social skills development in children with autism spectrum disorders: a review of the intervention research. J Autism Dev Disord (2006) 2.46
Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry (2006) 2.45
Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry (2003) 2.33
Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry (2010) 2.32
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry (2013) 2.30
Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol (2011) 2.28
Stimulant medication use in children: a 12-year perspective. Am J Psychiatry (2012) 2.27
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 2.26
Challenges in evaluating psychosocial interventions for Autistic Spectrum Disorders. J Autism Dev Disord (2005) 2.23
The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry (2009) 2.13
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry (2009) 2.13
Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry (2011) 2.10
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry (2007) 2.03
What aspects of peer relationships are impaired in children with attention-deficit/hyperactivity disorder? J Consult Clin Psychol (2005) 2.03
Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol (2003) 2.02
Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry (2006) 2.00
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol (2007) 1.98